Roth Capital analyst Justin Clare raised the firm’s price target on Stem (STEM) to $23 from $13 and keeps a Neutral rating on the shares. The company delivered a mixed Q3, narrowed guidance ranges, and indicated that Stem is tracking toward the midpoint or better across all metrics, the analyst tells investors in a research note. Stem delivered the second quarter in a row of positive EBITDA as the strategic shift toward recurring software sales, along with cost cuts, have driven margin expansion and improved profitability, Roth added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STEM:
- Stem Inc: Transition to Software and Services Model Amid Stagnant Growth and Financial Challenges
- Stem, Inc. Reports Strong Q3 2025 Financial Results
- Stem Inc Issues Press Release with Form 8-K
- Stem reports Q3 revenue $38.2M, consensus $38.46M
- Stem narrows FY25 revenue view to $135M-$160M from $125M-$175M